HealthPolitics
STAT+: Lilly bypasses Australian pharmacies with DTC model
Publication: STAT
Author: Meghana Keshavan
Source published: 02/10/2026, 13:58:31 UTC
Briefing created: 03/10/2026, 03:08:29 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 03/10/2026, 03:07:23 UTC.
Briefings
A STAT analysis reports that Novartis paid $575 million to license an experimental Abogen Biosciences mRNA therapy, marking another instance of pharma seeking Chinese funding. The article notes NIH allocated $34 billion for the 2026 fiscal year but highlights a slow, opaque funding process complicating research. Coverage is limited to the specific Novartis transaction and the general NIH funding context, with no data on other pharmaceutical deals or specific research outcomes.
Key points
- Novartis paid $575 million to license an experimental Abogen Biosciences mRNA-based autoimmune therapy, representing a large pharma company seeking Chinese funding.
- The National Institutes of Health allocated $34 billion for the 2026 fiscal year, but a slower and increasingly opaque funding process is making it harder to conduct research.
Context and limitations
This briefing covers only the specific Novartis transaction and general NIH funding context. It does not include data on other pharmaceutical deals, specific research outcomes, or market forecasts for dengue or other diseases.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/10/2026, 03:08:29 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeigfeoeab33wr7yv3priiuk7kudj36aig54ken4w4bvzrlt2prlfla